[{"id":"bc4bd5fe-eb27-4217-b824-f4e3646427cd","acronym":"UPCC 02112","url":"https://clinicaltrials.gov/study/NCT01594216","created_at":"2021-01-18T06:48:41.179Z","updated_at":"2024-07-02T16:34:26.790Z","phase":"Phase 2","brief_title":"Ruxolitinib in Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01594216 - UPCC 02112","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/09/2016","study_completion_date":" 04/09/2016","last_update_posted":"2024-06-12"},{"id":"782accc5-d280-4011-b282-a7d44c7401ad","acronym":"haplo-HCT","url":"https://clinicaltrials.gov/study/NCT03755414","created_at":"2022-05-12T21:54:02.090Z","updated_at":"2024-07-02T16:35:15.228Z","phase":"Phase 1","brief_title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03755414 - haplo-HCT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2024-03-12"},{"id":"2616fda1-27bb-45e0-aa28-222708cf4e67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014360","created_at":"2021-08-20T14:52:57.168Z","updated_at":"2024-07-02T16:35:46.607Z","phase":"Phase 1b","brief_title":"A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT05014360","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" APC • STAT3","pipe":" | ","alterations":" APC mutation","tags":["APC • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-06-02"},{"id":"ad4e10c2-059c-4cf0-8bb4-0e41acbf3018","acronym":"Ruxo-EPO","url":"https://clinicaltrials.gov/study/NCT03208803","created_at":"2021-01-18T15:49:31.299Z","updated_at":"2024-07-02T16:36:07.098Z","phase":"","brief_title":"Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis","source_id_and_acronym":"NCT03208803 - Ruxo-EPO","lead_sponsor":"Centre Hospitalier Annecy Genevois","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2022-07-20"},{"id":"ea39bf9b-3a98-46eb-8bfc-59230c1a4e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395780","created_at":"2022-05-27T11:56:31.465Z","updated_at":"2024-07-02T16:36:09.466Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05395780","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-02"},{"id":"c7c7b388-a345-4c9d-9046-42dc16d8c6a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369286","created_at":"2022-05-11T16:55:50.518Z","updated_at":"2024-07-02T16:36:10.590Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05369286","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-11"},{"id":"d384b94e-6fc8-48b6-bbe8-626e4e7ac7cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01994382","created_at":"2021-01-18T09:05:54.582Z","updated_at":"2024-07-02T16:36:14.056Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","source_id_and_acronym":"NCT01994382","lead_sponsor":"Alexion Pharmaceuticals","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • cerdulatinib (ALXN2075)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 08/30/2013","start_date":" 08/30/2013","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 12/15/2020","study_completion_date":" 12/15/2020","last_update_posted":"2022-04-05"},{"id":"b185f5af-b20b-432d-b8f0-d2a61b2a09b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412292","created_at":"2021-01-18T16:50:05.305Z","updated_at":"2024-07-02T16:36:18.334Z","phase":"Phase 1","brief_title":"MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)","source_id_and_acronym":"NCT03412292","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FLT3 • FGFR","pipe":" | ","alterations":" FLT3 wild-type","tags":["FLT3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-19"},{"id":"910f01e8-e129-4f75-9739-81c5fb413c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130021","created_at":"2021-11-22T14:53:41.790Z","updated_at":"2024-07-02T16:36:19.855Z","phase":"Phase 2","brief_title":"A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT05130021","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS wild-type","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Max-40279"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2021-12-06"}]